Skip to main content
Premium Trial:

Request an Annual Quote

Avi Nash, Jai Nagarkatti, Scott W. Binder

Premium

Sigma-Aldrich's board of directors elected Avi Nash as a director, the company said last week.

Nash currently heads a management consulting firm, Avi Nash LLC, launched in 2003. Prior to this, he was a partner at Goldman Sachs. He has worked at Booz, Allen & Hamilton and UOP.

The board also appointed Jai Nagarkatti, president and chief operating officer of the company since 2004, as president and chief executive officer to replace outgoing CEO David Harvey, who will remain chairman of the board.

Also elected to the board, Nagarkatti's appointment takes effect on Jan. 1, 2006.

Nagarkatti has been with Sigma-Aldrich for 29 years in R&D, production, operations and sales and marketing. He has a Master's degree in chemistry from Osmania University in Hyderabad, India, and a Ph.D. in organic chemistry from Texas A&M University.


Pathologist Scott W. Binder has joined CombiMatrix's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, as a member of its Scientific Advisory Board, Acacia Research said earlier this week.

A professor of clinical pathology and dermatology, chief of dermatopathology, and director of pathology outreach services at the David Geffen School of Medicine at UCLA, he is the founder and director of a dermatopathology fellowship training program in California.

Binder received his B.A. and M.D. from the University of Chicago Medical School, completed his residency at the Department of Pathology and Laboratory Medicine at UCLA, and was a fellow with at the Scripps Clinic and Research Institute in La Jolla, CA. He completed a preceptorship at New York University.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.